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Abstract
Background: Snake and insect venoms have been demonstrated to have beneficial effects in the
treatment of certain diseases including drug resistant human immunodeficiency virus (HIV)
infection. We evaluated and hypothesized the probable mechanisms of venoms against HIV.
Methods: Previous literatures published over a period of 30 years (1979-2009) were searched
using the key words snake venom, insect venom, mechanisms and HIV. Mechanisms were identified
and discussed.
Results & Conclusion: With reference to mechanisms of action, properties and components of
snake venom such as sequence homology and enzymes (protease or L- amino acid oxidase) may
have an effect on membrane protein and/or act against HIV at multiple levels or cells carrying HIV
virus resulting in enhanced effect of anti-retroviral therapy (ART). This may cause a decrease in
viral load and improvement in clinical as well as immunological status. Insect venom and human
Phospholipase A2 (PLA2) have potential anti-viral activity through inhibition of virion entry into the
cells. However, all these require further evaluation in order to establish its role against HIV as an
independent one or as a supplement.
Background
Components of snake venom are used for health and dis-
eases[1], an interesting emerging concept. Some of the
snake venom preparations include angiotensin-convert-
ing enzyme (ACE) inhibitor, disintegrins (antiplatelet
aggregants)[2] and also used, in diagnostic assays of vari-
ous blood coagulation factors[3]. Alpha neurotoxin,
extracted from cobras has been shown to have analgesic
effects [4,5] and crotoxin from Crotalus durissus terrificus
has cytotoxic effects[6]. Recently, Alrajhi and Almo-
haizeie[7] demonstrated the usefulness of snake venom in
a patient suffering from a drug resistant human immuno-
deficiency virus (HIV) infection, who was on anti-retrovi-
ral therapy (ART). In HIV patients, the response after
administration of snake venom preparation [7,8] was an
increase in CD4 count and decrease in viral load. We have
recently shown that the components of snake venom
might enhance the activity of ART at different levels[9].
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Interestingly, insect venom and human secretions also
have anti-HIV activity [10-12]. Hence, we evaluated and
hypothesized the probable mechanisms of venoms and
secretions against HIV infection.
Methods
Previous literatures published over a period of 30 years
(1979-2009) were searched using the key words snake
venom, insect venom, HIV and mechanisms. Based on the
available materials, the probable mechanisms of action of
venom and secretions against HIV were identified and dis-
cussed.
Results and Discussion
Snake Venom
The pharmacological activities of snake venom are com-
plex in nature with little known about them and it varies
amongst the multitude of snake venoms. The mechanisms
of action of snake venom against HIV are mediated
through various levels [9], such as structural homology,
binding interference (receptor/enzyme), catalytic/inhibi-
tory activity through enzymes, and induction/interaction
at membrane level.
1) Structure
The HIV virus entry into cells is mediated through the
binding of envelope glycoprotein - gp120 [13]. There is a
striking homology between the sequence 164-174 of
short segment HIV-1 gp120 and the highly conserved 30-
40 amino acid residues of snake venom neurotoxins long
loop [14,15]. Thus, both may compete for the same recep-
tor or binding site and act against HIV.
F N I S T S I R G K V - HIV gp 120
C D K F C S I R G P V - alpha - cobratoxin (Naja naja sia-
mensis)
C D A F C S I R G K R - k - bungarotoxin (Bungarus multi-
cintus)
Structure 1: Amino acid sequences of HIV gp120 (164-
174) compared to alpha- cobratoxin and k- bungarotoxin
(30-40)[15].
2) Binding
a) Snake venom contains Phospholipase A2
(PLA2)[11,16], which protect human primary blood
leukocytes from the replication of various macrophage
and T cell-tropic human immunodeficiency virus 1
(HIV-1) strains. PLA2 which is found in the venom of
many snakes has been shown to block viral entry into
cells before virion uncoating through prevention of
intracellular release of viral capsid protein [16]. This is
mainly due to the specific interaction of PLA2 to host
cells and not due to catalytic activity.
b) Immunokine - an oxidized derivative of alpha -
cobra toxin (Naja naja siamensis), has been shown to
inhibit the infection of lymphocytes by HIV and Feline
immunodeficiency virus (FIV) through chemokine
receptors (CCR 5 and CXCR 4) [17].
3) Enzymatic activity
a) L- amino acid oxidase (LAO), present in the venom of
Trimeresurus stejnegeri[18], C. Atrox, P. australis[19]; inhib-
its infection and replication of HIV virus through P24
antigen in a dose dependant manner[18]. P24 antigen is a
core protein of HIV and its level associates with viral
load[20]. Besides the binding of protein to cell mem-
brane, hydrogen peroxide (H2O2) produced as a free rad-
ical could inhibit the infection/replication of HIV, thereby
further enhancing the anti viral activity. In contrast, cata-
lase - a scavenger of H2O2, reduces the anti- viral activity
[18].
b) Protein fragment isolated from Oxyuranus scutellatus
snake venom is a potent inhibitor of p24 antigen and
blocks viral replication of resistant strains [21].
c) Snake venom contains metalloprotease inhibi-
tors[16,22] which could prevent the production of new
viruses through inhibition of protease enzymes. HIV
infects a CD4 cell of a person's body and then it copies its
own genetic code into the cell's DNA. Then, CD4 cell is
"programmed" to make new HIV genetic material and
proteins. These proteins are degraded by HIV protease
enzyme and again these proteins are used to make func-
tional new HIV particles. Protease inhibitors are used to
block the protease enzyme and prevent the cell from pro-
ducing new viruses.
4) Effect on membrane protein
P-glycoprotein (P-gp), a membrane protein, is an energy-
dependent efflux transporter driven by ATP hydroly-
sis[23]. P-gp transports a wide range of substances with
diverse chemical structures. In general, P-gp substrates
appear to be lipophilic and amphiphatic, and are recog-
nized to play an important role in processes of absorp-
tion, distribution, metabolism, and excretion of many
clinically important drugs in humans [23]. Because of its
importance in pharmacokinetics, inhibition or induction
of P-gp by various components of snake venom can lead
to significant drug-drug interactions, thereby changing the
systemic or target tissue exposure of the protease inhibi-
tors. At the same time one has to remember genetic poly-
morphism of P-gp,[23] which has also been recorded
recently, because it may affect drug disposition and pro-
duce variable drug effects.AIDS Research and Therapy 2009, 6:25 http://www.aidsrestherapy.com/content/6/1/25
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Other Clinical Uses of Snake Venom
Neurotoxins from snake such as cobra venom activates
central cholinergic pathways by nicotine and nicotinic
agonists, which have been shown to elicit anti-nociceptive
effects in a variety of species and produces significant
analgesic effect [24,25]. PLA2 inhibitors (PLI) from snake
- Habu snake, Trimeresurus flavoridis have anti-enzymatic,
anti-myotoxic, anti-edema inducing, anti-cytotoxic, and
anti-bacterial activities - [26], and hence, used in neurode-
generative disorders such as trauma, Alzhiemers disease,
Parkinson's and brain tumors - [27]. Fibrolase from A.
contorix snake venom degrade α and β chains of fibrin and
used as a thrombolytic agent [28]. Snake venom RGD-dis-
integrins showed direct interaction in several tumor cell
lines. It blocks αvβ3 integrin in tumor cells, thus inhibited
their adhesion to the extra cellular matrix and thereby pre-
vents metastasis [29]. PLA2 from  Bothrops neweidii and
Naja Naja venom, was found to be cytotoxic towards
B16F10 melanoma and Ehrlich ascitic tumor cells, as an
anti-cancer drug [30]. Crotoxin, a pre-synaptic neurotoxin
has been tried as an anti-cancer agent in advanced cancer
patients [31]. VRCTC-310, a natural product with PLA2
from Crotalus Durissus terrificus and cardiotoxin from Naja
Naja atra, have inhibitory effect against human and
murine tumor cell lines, and have effective value in the
treatment of advanced solid cancers, which were refrac-
tory to other therapy [32].
Insect Venom
1. Gene expression
Melittin is a 26 amino acid amphipathic α-helical pep-
tide, a major component of bee venom [33]. The
cecropins are a family of antibacterial peptides 35-39
amino acids in length which occur in a number of
insect species and in mammals [34]. Like melittin,
they consist of two α-helices linked by a flexible seg-
ment, and contain amphipathic structures. Melittin
and cecropin act against a wide range of infectious
agents, including Gram-positive and Gram-negative
bacteria [35]. Whereas melittin is lytic for red blood
cells at high concentrations, cecropins do not lyse
erythrocytes or other eukaryotic cells [35] and appear
to be non-toxic for mammalian cells. Melittin has
been reported to inhibit replication of murine retrovi-
ruses, tobacco mosaic virus [36] and herpes simplex
virus [37] suggesting that melittin also displays antivi-
ral activity. Analogous to antibacterial activity, the
antiviral activity of melittin has been attributed to
direct lysis of viral membranes, as demonstrated for
murine retroviruses [38]. However, melittin also dis-
plays antiviral activity at much lower, non-virolytic
concentrations, as shown for T cells chronically
infected with HIV-1 [39]. Wachinger [10] et al.,
reported that melittin and cecropin A are shown to
suppress production of HIV-1 by acutely infected cells
and also, suppresses the HIV-1 replication by interfer-
ing with host cell-directed viral gene expression [10].
Melittin treatment of T cells reduces levels of intracel-
lular Gag and viral mRNAs, and decreases HIV long
terminal repeat (LTR) activity. Besides, HIV LTR activ-
ity is also reduced in human cells stably transfected
with melittin and cecropin genes.
2. Binding
i. Mammalian venom secreted PLA2 have been associ-
ated with a variety of biological effects. Fernard et al
[11] suggested that PLA2 protect human blood leuko-
cytes from the replication of various macrophage and
T cell-tropic HIV-1 strains. This is neither due to viru-
cidal nor cytotoxic effect on host cells; however PLA2
blocks viral entry into cells before virion uncoating,
independent of the receptor. Inhibitors and catalytic
products of PLA2 have no effect on HIV-1 infection
suggesting that PLA2 catalytic activity is not involved in
antiviral effect.
ii. Peptide p3bv, is a 21-25 aminoacids component
from secreted phospholipases of bee venom (bvPLA2)
[40]. The p3bv peptide inhibits the replication of HIV-
1 through prevention of the cell fusion process medi-
ated by T-lymphotropic HIV-1 envelope without the
effect of monocytotropic HIV-1. Then, p3bv inhibits
the binding of stromal cell factor-1 α (natural ligand
of CXCR4) and 12G5 (anti-CXCR4 monoclonal anti-
body). Overall, p3bv blocks the replication of T-lym-
photropic HIV-1 strains by interacting with CXCR4,
thereby blocking viral entry into cells.
iii. PLA2-I A from bee, and serpent venom showed in
vitro anti-HIV activity, which was due to the ability of
secretions to destabilize anchorage (heparans) and
fusion (cholesterol) receptors on HIV target cells [41].
Human PLA2
Interestingly, human PLA2 (group III PLA2) has significant
homology with bee venom PLA2 [42]. Several murine and
human group phospholipases such as II A, X, V, XII, II E,
I B, and II F have potential antibacterial effects against
gram positive and negative bacteria [43]. In individuals
repeatedly exposed to HIV but who remain uninfected,
several possible reasons for protection have been pro-
posed but not clearly elucidated [44].
1. Membrane
Kim et al., [12] suggested that human PLA2  and
human group X PLA2 (PLA2-X) have potential antiviral
activity against diverse lentiviruses by the degradation
of viral membrane. PLA2-X has high affinity for phos-
phatidylcholine, a phospholipid in outer plasma
membrane and hydrolyzes it. Viral membrane of HIV-AIDS Research and Therapy 2009, 6:25 http://www.aidsrestherapy.com/content/6/1/25
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1 is rich in phosphatidylcholine and sphingomyelin
and may be more susceptible to PLA2-X.
2. Binding
PLA2-X inhibits replication of both CXCR4 and CCR5
HIV-1 in human CD4 cells. This effect was observed
despite the resistance of viral preparations to lysis by
antibody-mediated complement activation, suggest-
ing that this action occur in cases even where the
acquired immunity is ineffective[12]. In view of the
above, anitiviral activity of human PLA2 expressed in
immune tissues and cells will be particularly interest-
ing to analyze in future [44].
Debate in PLA2 action
Kim et al., [12] concluded that enzymatic activity of PLA2-
X is necessary for antiviral effect, which contradict the
findings of Fernard et al., [11] where catalytic activity was
not required. Hence, further studies are needed to ascer-
tain its exact mechanism.
Conclusion
In view of the above mechanisms, snake venom might
reduce HIV load, thereby decreasing its effect and
enhances CD4 count. Insect venom and human PLA2 act
through PLA2 mediated inhibition of virion entry into
host cells. Hopefully, the use of venom preparation or a
synthetic molecule similar to snake/insect venom/human
secretions without adverse effects may open a new era of
anti-retroviral therapy against HIV or act as an adjuvant
not only for HIV but also to other viral infections. How-
ever, further research is required to ascertain the exact
mechanism of antiviral activity of snake and insect ven-
oms.
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